BPC-157 vs TB-500: what the research actually compares

What is being compared

This page compares two research materials on chemistry, on the shape of their published records, and on price. It does not compare outcomes, because neither literature supports an outcome claim outside the models it was measured in, and nothing here is guidance to do anything.

Chemistry

• BPC-157 - synthetic pentadecapeptide, 15 residues, unmodified. CAS 137525-51-0. Molecular weight around 1419.5 g/mol.
• TB-500 - a designation applied to thymosin beta-4, an endogenous 43-residue actin-sequestering peptide (INN timbetasin), and sometimes to a much shorter actin-binding fragment. CAS 77591-33-4. Molecular weight around 4963.4 g/mol for the full-length peptide.

The practical consequence is that BPC-157 has one plausible identity and TB-500 has two. That difference shows up on the certificate, not in the marketing.

The two literatures are shaped differently

BPC-157

Almost entirely rodent-based, unusually broad in the range of injury models cataloged, and concentrated in the output of one research group and its collaborators (Seiwerth et al., Frontiers in Pharmacology 2021; Jozwiak et al., Pharmaceuticals 2025). Human data are minimal: a registered Phase I study (NCT02637284) has no posted results and its public record has not been meaningfully updated since 2015.

TB-500 / thymosin beta-4

Predominantly preclinical, with rodent dermal wound-repair models among the earliest reports (Malinda et al., Journal of Investigative Dermatology 1999). Unlike BPC-157, it has a controlled human trial program, but in a narrow application: ophthalmic formulations evaluated in the randomised, placebo-controlled ARISE Phase 3 program in dry eye. Non-ophthalmic human evidence remains sparse.

So the honest summary is that one has breadth without depth and the other has a narrow slice of depth. Neither is approved by any regulator for the uses people search for.

Certificate differences worth knowing

For BPC-157, a short unmodified peptide, a clean chromatogram and a matching mass are a straightforward ask.

For TB-500, the observed mass is doing extra work: it is the only thing that tells you whether you have full-length thymosin beta-4 or a fragment. A vendor who will not state which one they ship should be assumed to be shipping the cheaper one.

Price

At the premium end of the market these two diverge sharply - our snapshot has one vendor at $14.40/mg for BPC and $19.00/mg for TB. At volume they converge, because at scale the cost driver is synthesis throughput rather than sequence length.

Effect prices both 10mg vials at $39.99 list ($4.00/mg).

Why they are sold as a blend

The two are commonly co-lyophilized into a single vial and sold under the Wolverine label. That is a packaging and purchasing convention, not a research finding, and the honest way to evaluate it is against the cost of buying both components separately - which is exactly how we present it on the stack page.

Identity comes before literature

A comparison cannot begin until both materials are defined. BPC-157 is usually described as a specific 15-residue sequence. TB-500 is used less consistently and may refer to full-length thymosin beta-4 or to a shorter fragment associated with part of its biological activity.

That naming difference changes molecular mass, synthesis complexity and which papers are relevant. A vendor page that says only TB-500 has not provided enough information for a matched chemical or price comparison. Ask for the sequence definition before comparing results.

The two compounds are therefore not substitute versions of one research target. They have different sequences, biological histories and analytical risks. Placing them in one table is useful only if the table preserves those differences.

Build a literature matrix instead of a claim list

For each paper, record the exact material, model or population, route or formulation, comparator, primary endpoint, duration, authorship and replication status. This converts a pile of citations into a map that can be compared without stripping away experimental context.

BPC-157's published record is dominated by laboratory and animal work and is concentrated among connected investigators. TB-4 research also contains extensive preclinical work, plus a narrow lane of human ophthalmic development. The presence of human participants in one formulation does not generalize to every material using the TB-500 label.

The matrix should leave empty cells empty. No public result is not a negative result, and a registered study with no posted findings should not be presented as completed evidence. Honest gaps are more informative than a confident sentence assembled from unlike studies.

Breadth, depth and independence

Breadth asks how many distinct models or endpoints have been studied. Depth asks whether the same question has progressed through stronger designs. Independence asks whether unrelated groups reproduced the finding. A literature can be broad without being deep or independent.

These dimensions explain why citation counts are a poor ranking tool. Ten papers from one research network across ten induced models do not answer the same question as several independent replications of one prespecified endpoint. Both records may be informative, but in different ways.

Review articles are navigation tools in this process. They help locate mechanisms and primary studies, but they do not create new experimental units. The underlying design still sets the strength and scope of each statement.

The analytical plans should not be identical

For a short unmodified sequence such as BPC-157, expected mass and chromatographic composition can be addressed with a relatively direct specification. The record still needs sample linkage, method details and measured quantity, but the molecular target is less ambiguous.

For TB-500, the first analytical risk is the identity behind the alias. The expected mass should distinguish full-length thymosin beta-4 from a fragment. A purity result cannot resolve that difference because a fragment could itself produce a dominant chromatographic peak.

Longer sequences also create more opportunities for deletion and closely related products. That makes the trace, peak table and mass comparison especially important. One shared generic COA template should not replace analyte-specific acceptance criteria.

How to evaluate a combined vial

A blend should be specified as two target analytes with intended quantities, not as one total mass and one purity headline. The laboratory method must be able to separate or otherwise quantify the components and should state which purity result belongs to which component or signal.

Total measured mass can confirm the observed combined quantity under the selected method, but it does not prove the intended ratio. Two component measurements provide more information than a single total. Public summaries should not imply component precision when only total quantity was reported.

Price the blend against matched quantities of the defined standalone materials. A total dollars-per-milligram figure counts unlike components as interchangeable and can make a high share of a lower-cost component look like a bargain on the entire vial.

Interpreting the historical sample summaries

The public table includes separate historical third-party sample results for BPC-157, TB-500 and a combined BPC-157/TB-500 vial. The table exposes labeled mass, measured mass and reported purity while withholding report credentials and verification details.

Those rows are observations about the submitted samples. They are not proof that every product with the same name or size will match the result, and they are not presented as lot certificates for future Effect inventory.

Their main educational value is structural: the reader can see that labeled mass, measured mass and purity are separate fields, and that a blend needs a more careful identity record than a single total number.

A defensible comparison workflow

1. Define the exact BPC-157 and TB-500 sequences and expected masses.
2. Separate cell, animal, ophthalmic and other human records in the evidence matrix.
3. Track independence and replication rather than counting citations alone.
4. Set analyte-specific identity, purity, quantity and lot-linkage requirements.
5. For a blend, require component clarity and compare its price with matched standalone quantities.
6. Keep all conclusions within the model, formulation and sample actually studied or tested.

This workflow produces a narrower conclusion than marketing copy usually offers. That is a strength: every line remains traceable to a molecule, a study design, an analytical result or a price record.

Frequently asked